ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Sun Pharma gets U.S. subpoena

by Marc S. Reisch
June 6, 2016 | APPEARED IN VOLUME 94, ISSUE 23

The Indian generic drug maker Sun Pharmaceutical Industries is the latest drug company to receive an inquiry on pricing from U.S. authorities. Sun Pharma says its U.S. subsidiary received a grand jury subpoena from the Department of Justice’s antitrust division seeking information on generic drug pricing and communications with competitors and others on the sale of generics. The probe comes as Congress is pressuring regulators to investigate rising generic drug prices. Other generic drug makers including Dr. Reddy’s Laboratories, Allergan, and Par Pharmaceutical received subpoenas last year.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment